The New England Regional Center of Excellence will use the Developmental Projects program to promote innovative, cutting edge research in areas that may yield discoveries that would translate into the creation of new vaccines, therapeutics and/or diagnostics to combat NIAID priority pathogens and agents of emerging infectious disease. The Developmental Projects resources will be invested in research projects with the greatest potential to grow to full NERCE research programs or to projects that would be competitive for traditional NIH funding. Given the relatively short duration of support (one or two years) and the relatively small investment, the Developmental Projects will be more risky and require less preliminary data than conventional """"""""RO1""""""""-like grants. Developmental Project funds will also be used to help established New England investigators develop projects to the stage where they can take advantage of the NERCE core facilities. The fund will be used to attract investigators who are not working in the area of biodefense to begin research programs on priority pathogens and to attract investigators from institutions and companies that are not participating in NERCE. Finally, the Developmental Projects program will be used to encourage collaborations among investigators, particularly between basic and clinical research laboratories and between traditional microbiology laboratories and investigators in other basic science disciplines (e.g. immunologists, cell biologists, chemical biologists, bioinformaticists). In order to create the most fertile environment for discovery, developmental funds will be used to make strategic investments in projects of high risk but potentially high return preferentially over conventional small grants that are more likely to attract traditional NIH funding.
The Developmental Projects program will support early stage projects related to biodefense and emerging infectious disease pathogens. These projects will have a relatively high risk / reward profile and will also serve to attract new investigators to the field.
|de Wispelaere, Melissanne; Lian, Wenlong; Potisopon, Supanee et al. (2018) Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem Biol 25:1006-1016.e8|
|Huang, Nai-Jia; Pishesha, Novalia; Mukherjee, Jean et al. (2017) Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin. Nat Commun 8:423|
|Mertins, Philipp; Przybylski, Dariusz; Yosef, Nir et al. (2017) An Integrative Framework Reveals Signaling-to-Transcription Events in Toll-like Receptor Signaling. Cell Rep 19:2853-2866|
|Nair, Dhanalakshmi R; Chen, Ji; Monteiro, João M et al. (2017) A quinolinol-based small molecule with anti-MRSA activity that targets bacterial membrane and promotes fermentative metabolism. J Antibiot (Tokyo) 70:1009-1019|
|Choo, Min-Kyung; Sano, Yasuyo; Kim, Changhoon et al. (2017) TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects. J Exp Med 214:1297-1311|
|de Wispelaere, Mélissanne; Carocci, Margot; Liang, Yanke et al. (2017) Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res 139:171-179|
|Umetsu, Dale T (2017) Mechanisms by which obesity impacts upon asthma. Thorax 72:174-177|
|Zheng, Huiqing; Colvin, Christopher J; Johnson, Benjamin K et al. (2017) Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence. Nat Chem Biol 13:218-225|
|Coulson, Garry B; Johnson, Benjamin K; Zheng, Huiqing et al. (2017) Targeting Mycobacterium tuberculosis Sensitivity to Thiol Stress at Acidic pH Kills the Bacterium and Potentiates Antibiotics. Cell Chem Biol 24:993-1004.e4|
|Chiaraviglio, Lucius; Kang, Yoon-Suk; Kirby, James E (2016) High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity. J Vis Exp :|
Showing the most recent 10 out of 417 publications